Geoffrey Porges
Stock Analyst at Leerink Partners
(1.50)
# 3,423
Out of 5,182 analysts
114
Total ratings
47.37%
Success rate
-1.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Outperform | $36 → $49 | $26.00 | +88.46% | 9 | Mar 2, 2026 | |
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $26.53 | +111.08% | 10 | Dec 15, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $721.05 | +17.88% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $66.35 | -27.66% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $331.11 | -34.76% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $205.03 | -34.16% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $28.82 | -61.83% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $136.30 | -44.97% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $43.77 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $16.94 | -40.97% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $427.65 | -59.08% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $31.36 | +167.86% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $50.53 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.29 | +736.76% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $190.68 | - | 8 | Mar 16, 2017 |
Arcus Biosciences
Mar 2, 2026
Maintains: Outperform
Price Target: $36 → $49
Current: $26.00
Upside: +88.46%
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $26.53
Upside: +111.08%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $721.05
Upside: +17.88%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $66.35
Upside: -27.66%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $331.11
Upside: -34.76%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $205.03
Upside: -34.16%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $28.82
Upside: -61.83%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $136.30
Upside: -44.97%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $43.77
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $16.94
Upside: -40.97%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $427.65
Upside: -59.08%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $31.36
Upside: +167.86%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $50.53
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.29
Upside: +736.76%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $190.68
Upside: -